See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Prime Day
Amazon
James Gunn
Artificial Intelligence
Social Media
Natural Disasters
Donald Trump
Novak Djokovic
Floods
Democratic Party
Crime
Education
Published • loading... • Updated

Managing Dose Reductions With Bispecific Therapies in Myeloma

Summary by targetedonc.com
During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Managing Dose Reductions With Bispecific Therapies in Myeloma

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Tuesday, July 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal